Laigo Bio

Laigo's proprietary SureTAC platform empowers us to rapidly develop first-in-class dual targeted therapies that eliminate disease-driving membrane targets using straightforward bispecific antibody technology. We are committed to exploring an ever-evolving universe of new targets, including those currently considered undruggable, and we are open to strategic partnerships to make meaningful advancements in treating diseases that lack effective treatment options today. Laigo Bio is where innovation meets life-changing solutions, forging a path toward a healthier tomorrow. #TPD #Protac #membraneprotein #bispecificantibody #antibody #proteindegradation #roteindegrader #LaigoBio #oncology #neurobiology #immunology #SureTACs